468 related articles for article (PubMed ID: 18294802)
1. Clinical course and outcomes of methamphetamine-dependent adults with psychosis.
Glasner-Edwards S; Mooney LJ; Marinelli-Casey P; Hillhouse M; Ang A; Rawson R;
J Subst Abuse Treat; 2008 Dec; 35(4):445-50. PubMed ID: 18294802
[TBL] [Abstract][Full Text] [Related]
2. Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes.
Marinelli-Casey P; Gonzales R; Hillhouse M; Ang A; Zweben J; Cohen J; Hora PF; Rawson RA;
J Subst Abuse Treat; 2008 Mar; 34(2):242-8. PubMed ID: 17596903
[TBL] [Abstract][Full Text] [Related]
3. Impulsivity and positive psychotic symptoms influence hostility in methamphetamine users.
Lapworth K; Dawe S; Davis P; Kavanagh D; Young R; Saunders J
Addict Behav; 2009 Apr; 34(4):380-5. PubMed ID: 19097704
[TBL] [Abstract][Full Text] [Related]
4. A review of the clinical pharmacology of methamphetamine.
Cruickshank CC; Dyer KR
Addiction; 2009 Jul; 104(7):1085-99. PubMed ID: 19426289
[TBL] [Abstract][Full Text] [Related]
5. Socio-demographic factors associated with methamphetamine treatment contact among dependent methamphetamine users in Sydney, Australia.
McKetin R; Kelly E
Drug Alcohol Rev; 2007 Mar; 26(2):161-8. PubMed ID: 17364851
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of psychotic symptoms among methamphetamine users.
McKetin R; McLaren J; Lubman DI; Hides L
Addiction; 2006 Oct; 101(10):1473-8. PubMed ID: 16968349
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants.
McKetin R; Ross J; Kelly E; Baker A; Lee N; Lubman DI; Mattick R
Drug Alcohol Rev; 2008 May; 27(3):277-85. PubMed ID: 18368609
[TBL] [Abstract][Full Text] [Related]
8. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.
McKetin R; Lubman DI; Baker AL; Dawe S; Ali RL
JAMA Psychiatry; 2013 Mar; 70(3):319-24. PubMed ID: 23303471
[TBL] [Abstract][Full Text] [Related]
9. The effects of modafinil treatment on neuropsychological and attentional bias performance during 7-day inpatient withdrawal from methamphetamine dependence.
Hester R; Lee N; Pennay A; Nielsen S; Ferris J
Exp Clin Psychopharmacol; 2010 Dec; 18(6):489-97. PubMed ID: 21186923
[TBL] [Abstract][Full Text] [Related]
10. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence.
Rawson RA; Marinelli-Casey P; Anglin MD; Dickow A; Frazier Y; Gallagher C; Galloway GP; Herrell J; Huber A; McCann MJ; Obert J; Pennell S; Reiber C; Vandersloot D; Zweben J;
Addiction; 2004 Jun; 99(6):708-17. PubMed ID: 15139869
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
[TBL] [Abstract][Full Text] [Related]
12. Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders.
Temmingh HS; van den Brink W; Howells F; Sibeko G; Stein DJ
J Dual Diagn; 2020; 16(2):208-217. PubMed ID: 31984872
[No Abstract] [Full Text] [Related]
13. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment.
Lecomte T; Mueser KT; MacEwan W; Thornton AE; Buchanan T; Bouchard V; Goldner E; Brink J; Lang D; Kang S; Barr AM; Honer WG
J Nerv Ment Dis; 2013 Dec; 201(12):1085-9. PubMed ID: 24284645
[TBL] [Abstract][Full Text] [Related]
14. Technology and innovation in the psychosocial treatment of methamphetamine use, risk and dependence.
Kay-Lambkin FJ
Drug Alcohol Rev; 2008 May; 27(3):318-25. PubMed ID: 18368614
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence.
Shearer J; Darke S; Rodgers C; Slade T; van Beek I; Lewis J; Brady D; McKetin R; Mattick RP; Wodak A
Addiction; 2009 Feb; 104(2):224-33. PubMed ID: 19149817
[TBL] [Abstract][Full Text] [Related]
16. Electrocardiographic abnormalities in methamphetamine abusers.
Haning W; Goebert D
Addiction; 2007 Apr; 102 Suppl 1():70-5. PubMed ID: 17493055
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine and its impact on dental care.
Klasser GD; Epstein J
J Can Dent Assoc; 2005 Nov; 71(10):759-62. PubMed ID: 16324229
[TBL] [Abstract][Full Text] [Related]
18. Stepping through treatment: reflections on an adaptive treatment strategy among methamphetamine users with depression.
Kay-Lambkin FJ; Baker AL; McKetin R; Lee N
Drug Alcohol Rev; 2010 Sep; 29(5):475-82. PubMed ID: 20887570
[TBL] [Abstract][Full Text] [Related]
19. Treatment response by primary drug of abuse: does methamphetamine make a difference?
Luchansky B; Krupski A; Stark K
J Subst Abuse Treat; 2007 Jan; 32(1):89-96. PubMed ID: 17175402
[TBL] [Abstract][Full Text] [Related]
20. Methamphetamine use by incarcerated women: comorbid mood and anxiety problems.
Vik PW
Womens Health Issues; 2007; 17(4):256-63. PubMed ID: 17544297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
